SG11201811831SA - Compositions and methods for stabilizing flaviviruses with improved formulations - Google Patents

Compositions and methods for stabilizing flaviviruses with improved formulations

Info

Publication number
SG11201811831SA
SG11201811831SA SG11201811831SA SG11201811831SA SG11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA
Authority
SG
Singapore
Prior art keywords
urea
sucrose
trehalose
msg
alanine
Prior art date
Application number
SG11201811831SA
Inventor
Jill Livengood
Linda Strange
Steven Erb
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG11201811831SA publication Critical patent/SG11201811831SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) --„, (19) World Intellectual Property 11111111111111111111111111111111111111110111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .......'\"' WO 2018/027075 Al 08 February 2018 (08.02.2018) WIP0 I PCT (51) International Patent Classification: chusetts 01701 (US). ERB, Steven, Michael; 2207 Tangle- A611 f 39/12 (2006.01) A61K 39/00 (2006.01) wood Drive, Fort Collins, Colorado 80525 (US). (21) International Application Number: (74) Agent: HANSON, Roberta et al.; 2200 Wells Fargo PCT/US2017/045375 Center, 90 South Seventh St., Minneapolis, Minnesota 55402-3901 (US). (22) International Filing Date: 03 August 2017 (03.08.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/370,611 03 August 2016 (03.08.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: TAKEDA VACCINES, INC. [US/US]; One MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Takeda Parkway, Deerfield, Illinois 60015 (US). OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors: LWENGOOD, Jill, Ann; 2348 Hampshire TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Court, Fort Collins, Colorado 80526 (US). STRANGE, Linda, Marie; 65 Hemenway Road, Framingham, Massa- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, = (54) Title: COMPOSITIONS AND METHODS FOR STABILIZING = Potency Loss after 5 weeks at 25°C ion in 1 i itol Sucrose BB+Meth e+MSG+A an ne+Urea+Mann FLAVIVIRUSES WITH IMPROVED FORMULATIONS IM 1 Trehalose BB+Methionine+MSG+Alanine+Urea+Mannitol = Sucrose BB+Methionine+Urea 1 Alanine: 10 tuM Mannitol: 5% = Trehalose BB+Mannitol Methionine: 2.5 inM Monosodium Glutamate: 10mM = Sucrose BB+Alanine+Urea Urea: 0.25% = Sucrose BB+Arginine+Urea Trehalose BB+ A rgi n ne+Urea i = = Trehalose BB+MSG+Urea , 1 Sucrose BB+Methionine+MSG+Alanine+Urea = Sucrose BB+Urea Trehalose BB+ Methionine+Urea . 0 = = • = Trehalose BB+Methionine+MSG+Alanine+Urea Log Los of _ Trehalose BB+Urea = Trehalose BB+Alanine+Urea Sucrose BB+Methionine+MSG+Alanine = Sucrose BB MSG + (10mM) +Urea (0.25%) Sucrose BB+Mannitol Control/Reference Formulation FIG. 1 -030 If) IN c ::: :) (57) : Embodiments herein relate to compositions and IN sitions and methods disclosed herein concern stabilizing live, e •1 0 ments relate to compositions and methods for reducing degradation —. relate to improved formulations for prolonging stabilization of 0 1-1 0 age ' accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable © applications and methods. ei -0.20 -0.10 methods for stabilizing Flaviviruses. In certain embodiments, compo- attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodi- of live, attenuated or unattenuated flaviviruses. live attenuated 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 Titer Loss (log i „ PFU/dose) or unattenuated Flaviviruses during manufacturing, stor- Other embodiments O [Continued on next page] WO 2018/027075 Al MIDEDIMOMOIDEIRDERIONIONOBIENBUDIMI GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) Published: — with international search report (Art. 21(3))
SG11201811831SA 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations SG11201811831SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370611P 2016-08-03 2016-08-03
PCT/US2017/045375 WO2018027075A1 (en) 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations

Publications (1)

Publication Number Publication Date
SG11201811831SA true SG11201811831SA (en) 2019-01-30

Family

ID=59593235

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913040SA SG10201913040SA (en) 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations
SG11201811831SA SG11201811831SA (en) 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913040SA SG10201913040SA (en) 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations

Country Status (14)

Country Link
US (3) US10835597B2 (en)
EP (1) EP3493839A1 (en)
JP (2) JP7280179B2 (en)
KR (2) KR102576789B1 (en)
CN (1) CN109789200A (en)
AU (2) AU2017305498B2 (en)
BR (1) BR112019001299A2 (en)
CA (1) CA3030343A1 (en)
CO (1) CO2019001448A2 (en)
MX (2) MX2019001473A (en)
PH (1) PH12019500003A1 (en)
SG (2) SG10201913040SA (en)
TW (2) TWI766876B (en)
WO (1) WO2018027075A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984357B (en) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 Vaccine protectant composition and Gripovax without gelatin
MX2020005857A (en) 2017-12-07 2020-09-09 Merck Sharp & Dohme Formulations of dengue virus vaccine compositions.
WO2019178687A1 (en) 2018-03-20 2019-09-26 National Research Council Of Canada A method for lyophilizing live vaccine strains of francisella tularensis
KR102646145B1 (en) 2018-05-31 2024-03-11 주식회사 엑소코바이오 Composition for reducing skin pore size comprising an exosome derived from stem cell as an active ingredient
WO2020027466A1 (en) 2018-07-28 2020-02-06 주식회사 엑소코바이오 Method for lyophilizing exosome
KR102163806B1 (en) 2018-07-30 2020-10-07 주식회사 엑소코바이오 Composition for reducing sebum release comprising an exosome derived from stem cell as an active ingredient
BR112022001476A2 (en) 2019-08-16 2023-10-03 Takeda Vaccines Inc USE OF A HEPATITIS A VACCINE AND A DENGUE VACCINE COMPOSITION OR A UNIT DOSE OF A DENGUE VACCINE COMPOSITION, VACCINE AND KIT COMBINATION
BR112022015710A2 (en) * 2020-02-27 2022-09-27 Takeda Vaccines Inc METHOD TO REMOVE HOST CELL DNA FROM VIRUS PREPARATION
WO2021168764A1 (en) * 2020-02-28 2021-09-02 台湾粒线体应用技术股份有限公司 Cryopreservation agent and mitochondrion cryopreserving method using same
CN113549653B (en) * 2020-04-23 2024-03-22 上海赛比曼生物科技有限公司 Combination reagent for long-term storage of lentiviral vectors
CN111588859B (en) * 2020-06-02 2021-09-03 成都可恩生物科技有限公司 Freeze-drying protective agent and application thereof, freeze-dried seedling and preparation method thereof
CN112501024A (en) * 2020-12-03 2021-03-16 英科新创（苏州）生物科技有限公司 Universal quality control product preservation solution for in-vitro diagnosis kit
EP4012025A1 (en) * 2020-12-10 2022-06-15 Univerzita Palackého v Olomouci Transport medium for samples containing nucleic acids and/or proteins
CN113730592B (en) * 2021-09-03 2023-12-19 吉林正业生物制品股份有限公司 Duck tembusu virus live vaccine freeze-drying protective agent and preparation method and application thereof
EP4356925A3 (en) * 2022-10-18 2024-05-01 Takeda Vaccines, Inc. Dengue vaccine formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
EP2851087B1 (en) * 2006-11-07 2017-04-19 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
KR102134980B1 (en) 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 Methods and compositions for live attenuated viruses
EP2143440A1 (en) * 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
CN104984357B (en) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 Vaccine protectant composition and Gripovax without gelatin
EP3442571A1 (en) * 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults

Also Published As

Publication number Publication date
US20210121558A1 (en) 2021-04-29
US10835597B2 (en) 2020-11-17
KR20230132887A (en) 2023-09-18
JP2019524771A (en) 2019-09-05
MX2022010907A (en) 2022-10-07
SG10201913040SA (en) 2020-03-30
CN109789200A (en) 2019-05-21
KR102576789B1 (en) 2023-09-12
CO2019001448A2 (en) 2019-04-30
EP3493839A1 (en) 2019-06-12
TW201807191A (en) 2018-03-01
CA3030343A1 (en) 2018-02-08
TW202309276A (en) 2023-03-01
WO2018027075A1 (en) 2018-02-08
AU2017305498B2 (en) 2023-03-30
US20190184004A1 (en) 2019-06-20
PH12019500003A1 (en) 2019-10-14
TWI766876B (en) 2022-06-11
JP2023052624A (en) 2023-04-11
MX2019001473A (en) 2019-09-23
AU2023203715A1 (en) 2023-07-06
KR20190034598A (en) 2019-04-02
JP7280179B2 (en) 2023-05-23
AU2017305498A1 (en) 2019-01-24
BR112019001299A2 (en) 2019-04-30
US11701421B2 (en) 2023-07-18
US20230263880A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
SG11201811831SA (en) Compositions and methods for stabilizing flaviviruses with improved formulations
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201803073TA (en) Insect singulator system
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201907891XA (en) Combination therapy for the treatment or prevention of tumours
SG11201807003UA (en) Smc combination therapy for the treatment of cancer
SG11201803906PA (en) Control of cellular redox levels
SG11201901501UA (en) Compositions and methods for enhancing cancer radiotherapy
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201805645QA (en) Lsd1 inhibitors
SG11201811074RA (en) Nant cancer vaccine
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201900975XA (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201805368YA (en) Anthelmintic depsipeptide compounds
SG11201810793XA (en) Pharmaceutical combinations
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201909837YA (en) Methods for treating lung disorders
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases